A review of the evidence to support interim reference level for dietary lead exposure in adults

FDA developed the interim reference level (IRL) for lead of 3 μg/day in children and 12.5 μg/day in women of childbearing age (WOCBA) to better protect the fetus from lead toxicity. These IRLs correspond to a blood lead level (BLL) of 0.5 μg/dL in both populations. The current investigation was perf...

Full description

Saved in:
Bibliographic Details
Published inRegulatory toxicology and pharmacology Vol. 111; p. 104579
Main Authors Dolan, Laurie C., Flannery, Brenna M., Hoffman-Pennesi, Dana, Gavelek, Alexandra, Jones, Olivia E., Kanwal, Richard, Wolpert, Beverly, Gensheimer, Kathleen, Dennis, Sherri, Fitzpatrick, Suzanne
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Inc 01.03.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:FDA developed the interim reference level (IRL) for lead of 3 μg/day in children and 12.5 μg/day in women of childbearing age (WOCBA) to better protect the fetus from lead toxicity. These IRLs correspond to a blood lead level (BLL) of 0.5 μg/dL in both populations. The current investigation was performed to determine if the IRL for WOCBA should apply to the general population of adults. A literature review of epidemiological studies was conducted to determine whether a BLL of 0.5 μg/dL is associated with adverse effects in adults. Some studies reported adverse effects over a wide range of BLLs that included 0.5 μg/dL adding uncertainty to conclusions about effects at 0.5 μg/dL; however, no studies clearly identified this BLL as an adverse effect level. Results also showed that the previously developed PTTDI for adults of 75 μg/day lead may not be health protective, supporting use of a lower reference value for lead toxicity in this population group. Use of the 12.5 μg/day IRL as a benchmark for dietary lead intake is one way FDA will ensure that dietary lead intake in adults is reduced. •FDA has an interim reference level (IRL) of 12.5 μg/day for dietary lead exposure in women of childbearing age.•The IRL corresponds to a blood lead level (BLL) of 0.5 μg/dL.•Epidemiology studies were reviewed to determine if a BLL of 0.5 μg/dL was associated with adverse effects in adults.•No studies clearly identified a BLL of 0.5 μg/dL as an adverse effect level.•The results support use of the 12.5 μg/day IRL for the general population of adults.
ISSN:0273-2300
1096-0295
DOI:10.1016/j.yrtph.2020.104579